Paula I. C.
- Country
- Spain
- Department
- Digestive
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Efficacy and Safety Evaluation of Pemafibrate and Tofogliflozin Combination in Noncirrhotic NASH with Liver Fibrosis: A Phase 2 Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 108 of 149 partner sites.
Specializations
Hepatic Disorders
The investigator specializes in treating nonalcoholic steatohepatitis (NASH) and its various manifestations. Their research encompasses both non-cirrhotic and cirrhotic forms of the disease, with particular attention to liver fibrosis progression.
- Non-cirrhotic NASH with fibrosis
- Compensated cirrhosis due to NASH
- NASH-related liver fibrosis
Their work extends to investigating innovative therapeutic approaches for hepatic conditions.
Metabolic Liver Disease
The investigator focuses on metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver conditions. Their expertise includes the study of novel therapeutic agents for metabolic liver disorders.
- Non-alcoholic fatty liver disease
- Metabolic liver dysfunction
- Liver fibrosis regression
Their research addresses the complex relationship between metabolic disorders and liver health.
Liver Complications
The investigator studies severe liver disease complications, including esophageal varices and drug-induced liver injury. Their research encompasses preventive strategies and therapeutic interventions.
- Hepatotoxicity management
- Portal hypertension complications
- Liver disease progression
Their work includes evaluating treatments for various forms of liver injury and their complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.